Drugs / iclaprim

Trials 5 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00543608 Nov 2007 → Apr 2009 nosocomial infection Arpida AG Terminated No outcome recorded
Phase 34 trials
Phase 3 NCT02600611 Nov 2015 → Jan 2017 Motif Bio Completed No outcome recorded
Phase 3 NCT02607618 Nov 2015 → Aug 2017 Motif Bio Completed No outcome recorded
Phase 3 NCT00303550 Mar 2006 → ? skin disease caused by bacterial infection Arpida AG Completed No outcome recorded
Phase 3 NCT00299520 Jun 2005 → Jul 2006 Arpida AG Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as iclaprim ClinicalTrials.gov intervention name — accepted as the source's own label NCT00299520
4

NCT02607618

NCT02600611

NCT00543608

NCT00303550

Known as AR-100 ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as AR-100.001 ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as Iclaprim mesilate ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as ICLAPRIM MESYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as Iclaprim methanesulfonate ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as Iclaprime ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as Iclaprimmonomesilate ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Known as RO 48-2622 ChEMBL registry synonym — accepted as the source's own label CHEMBL134561
Modality Small molecule “Iclaprim, a diaminopyrimidine antimicrobial, was compared with vancomycin for treatment of patients with acute bacterial skin and skin-structure infections (ABSSSIs) in two...” PMID 29783024 May 2018
Route Intravenous intravenous iclaprim or intravenous linezolid” NCT00299520